Irina Kulikovskaya

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando et al. · Nature Medicine · 2018 · 1.7K citations · Full text

T Cell Therapy, Cancer Immunosurveillance, Chronic Lymphocytic Leukemia +6

CRISPR-engineered T cells in patients with refractory cancer

Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis et al. · Science · 2020 · 1.4K citations · Full text

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

J. Joseph Melenhorst, Gregory M. Chen, Meng Wang et al. · Nature · 2022 · 851 citations · Full text

Hematological Malignancy, Decade-long Leukaemia Remissions, Malignant Blood Disorder +8

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

Aaron P. Rapoport, Edward A. Stadtmauer, Gwendolyn Binder-Scholl et al. · Nature Medicine · 2015 · 832 citations · Full text

Cancer Immunosurveillance, Immunology, Tumor Immunity +9

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Joseph A. Fraietta, Christopher L. Nobles, Morgan A. Sammons et al. · Nature · 2018 · 829 citations · Full text

Cd19-targeted T Cells, Cancer Immunosurveillance, Immunology +8